SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Adicet Bio, Inc. (ACET) (CIK 0001720580) (ACET) — Mar 18, 2026

Adicet Bio, Inc. (ACET) (CIK 0001720580)
Date: March 18, 2026 · CIK: 0001720580 · Accession: 0000000000-26-002754

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294265

Date
March 18, 2026
Author
Chen Schor
Form
UPLOAD
Company
Adicet Bio, Inc. (ACET) (CIK 0001720580)

Letter

March 18, 2026 Chen Schor Chief Executive Officer Adicet Bio, Inc. 131 Dartmouth Street, 3rd Floor Boston, MA 02116 Re:Adicet Bio, Inc. Registration Statement on Form S-3 Filed March 12, 2026 File No. 333-294265 Dear Chen Schor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gabriela Morales-Rivera, Esq.

Show Raw Text
March 18, 2026
Chen Schor
Chief Executive Officer
Adicet Bio, Inc.
131 Dartmouth Street, 3rd Floor
Boston, MA 02116
Re:Adicet Bio, Inc.
Registration Statement on Form S-3
Filed March 12, 2026
File No. 333-294265
Dear Chen Schor:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gabriela Morales-Rivera, Esq.